<SEC-DOCUMENT>0001628280-25-050415.txt : 20251107
<SEC-HEADER>0001628280-25-050415.hdr.sgml : 20251107
<ACCEPTANCE-DATETIME>20251107072706
ACCESSION NUMBER:		0001628280-25-050415
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251107
DATE AS OF CHANGE:		20251107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prime Medicine, Inc.
		CENTRAL INDEX KEY:			0001894562
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41536
		FILM NUMBER:		251460510

	BUSINESS ADDRESS:	
		STREET 1:		60 FIRST ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-465-0013

	MAIL ADDRESS:	
		STREET 1:		60 FIRST ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prme-20251107.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382a4ec3-91ca-422d-977a-87c88684cb64,g:f59cd3c8-7a12-4804-81c2-511ed736342b,d:7ec7cd290a61493aa49a3186bb7b507c-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>prme-20251107</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001894562</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="prme-20251107.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001894562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-07</xbrli:startDate><xbrli:endDate>2025-11-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7ec7cd290a61493aa49a3186bb7b507c_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;7, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Prime Medicine, Inc.</ix:nonNumeric></span></div><div style="margin-bottom:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:2.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.275%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(State or other jurisdiction of </span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-41536</ix:nonNumeric></span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">84-3097762</ix:nonNumeric></span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">60 First Street</ix:nonNumeric></span></div><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02141</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Zip Code)</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">465-0013</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">(Registrant's telephone number, including area code)</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.633%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:9pt;padding-right:7.9pt;text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.08pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:125%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common stock, par value $.00001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">PRME</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934 (&#167;250.12b-2 of this chapter).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div></div><div id="i7ec7cd290a61493aa49a3186bb7b507c_4"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;7, 2025, Prime Medicine, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results and business highlights for the quarter ended September&#160;30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:125%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:125%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">99.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="q320258-kex991xpressrelease.htm">Press Release, dated November 7, 2025, furnished herewith.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-right:1.85pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:0.9pt;padding-right:1.9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div></div><div id="i7ec7cd290a61493aa49a3186bb7b507c_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;7, 2025</span></div><div style="margin-bottom:9pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.660%"><tr><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.527%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-22">Prime Medicine, Inc.</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:1pt;padding-right:1.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt 2px 2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">/s/ Allan Reine</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:1pt;padding-right:1.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Allan Reine</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:1pt;padding-right:1.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt 2px 2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q320258-kex991xpressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i709b8635f3dd4eed88a7c4dcc949136e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:9pt;text-align:justify"><img alt="image.jpg" src="image.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- New preclinical data for PM577 in Wilson&#8217;s Disease (WD) to be presented at AASLD&#59; on-track to file IND and&#47;or CTA in H1&#8217;26, with initial clinical data expected in 2027 -- </font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD)&#59; on-track to file IND and&#47;or CTA in mid-2026, with initial clinical data expected in 2027 --</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer --</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Company to host virtual KOL event at 8&#58;00am ET on Wednesday, November 12, 2025 to showcase Wilson&#8217;s Disease Strategy -- </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cambridge, Mass.,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> November&#160;07, 2025 &#8211; Prime Medicine, Inc. (Nasdaq&#58; PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended September 30, 2025 and provided a business update.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We remain steadfast in executing our focused strategy, with efforts centered on advancing our liver-targeted programs in WD and AATD, our Cystic Fibrosis (CF) program as well as exploring additional collaborations &#8211; like our efforts with Bristol Myers Squibb &#8211; that can expand the reach and impact of our technology,&#8221; said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. &#8220;In recent months, we&#8217;ve made meaningful progress across these priorities. In August, we nominated PM647 as our development candidate for AATD, marking a significant step toward delivering a best-in-class therapy capable of correcting the mutant AATD protein back to normal. And, earlier this week, we welcomed Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer, adding a senior leader with deep experience in building companies through internal innovation and high-value strategic collaborations. Following our recent financing, we believe we are well positioned to continue executing across our pipeline and to leverage the versatility and broad reach of our platform to treat some of the most devastating genetic diseases.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Reine continued, &#8220;This progress continues as we enter the fourth quarter. This weekend, we&#8217;ll present new preclinical data with PM577 at AASLD, further reinforcing our belief that Prime Editing can precisely correct the disease-causing mutations in patients suffering from Wilson&#8217;s Disease.&#8221;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Prime Medicine&#8217;s Pipeline&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prime Medicine is currently advancing </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> programs to cure two of the largest genetic liver diseases, Wilson&#8217;s Disease (WD) and Alpha-1 Antitrypsin Deficiency (AATD). Prime Medicine expects to file an investigational new drug application (IND) and&#47;or clinical trial application (CTA) for its WD program in the first half of 2027 and for its AATD program in mid-2026&#59; initial clinical data from both studies are expected in 2027. </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prime Medicine is also advancing an in vivo Cystic Fibrosis (CF) program with support from the Cystic Fibrosis Foundation, and efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. Additionally, following positive proof-of-concept data from the first two patients treated in its Phase 1&#47;2 study of PM359 for the treatment of Chronic Granulomatous Disease (CGD), Prime Medicine plans to continue to engage in regulatory interactions with the U.S. Food and Drug Administration (FDA) to explore efficient ways to make this medicine available to patients in need.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><img alt="image.jpg" src="image.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Updates</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Today, Prime Medicine announced that it will present new preclinical data for PM577 at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting (November 7-11, 2025).  Details of the late-breaking poster presentation are as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Title&#58; Normalization of hepatic copper level detected by &#8310;&#8308;Cu PET imaging in mice treated with Prime Editor that precisely corrected ATP7B p.H1069Q mutation causing Wilson disease</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Date&#58; Sunday, November 9, 2025</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Time&#58; 8&#58;00am &#8211; 5&#58;00pm ET</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presentation Number&#58; 5032</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Session&#58; Sunday Late Breaking Posters </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2025, Prime Medicine nominated PM647 as its development candidate for the treatment of AATD. In fully humanized mouse models, treatment with PM647 achieved high levels of editing efficiency and demonstrated restoration of the corrected isoform (M-AAT) into the healthy human range at clinically relevant doses. PM647 is delivered using Prime Medicine&#8217;s universal liver lipid nanoparticle (LNP), which the Company believes may enable significant efficiencies in pre-clinical development, manufacturing and clinical development.  </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Corporate Updates&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2025, Prime Medicine announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer. Dr. Hawryluk will lead Prime Medicine&#8217;s business development, corporate strategy and alliance management functions, advancing the company&#8217;s efforts to expand the reach of Prime Editing through partnerships and collaborations.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prime Medicine will host a virtual KOL event on Wednesday, November 12, 2025, from 8&#58;00-9&#58;00am ET. This event will provide insight into Prime Medicine&#8217;s Wilson&#8217;s Disease strategy, with a focus on PM577. In addition to company management, the event will feature Dr. Michael Schilsky, Professor of Medicine at Yale School of Medicine and Medical Director of the Adult Liver Transplant program at Yale New Haven Transplantation Center. The event will be webcast live and those who intend to join can pre-register for the webcast here.</font></div><div id="i709b8635f3dd4eed88a7c4dcc949136e_4"></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2025 Financial Results</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Research and Development (R&#38;D) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> R&#38;D expenses were $44.0&#160;million for the three months ended September&#160;30, 2025, as compared to $40.3&#160;million for the three months ended September&#160;30, 2024. The increase in R&#38;D expenses is driven primarily by license and intellectual property costs and facility related expenses, offset by Prime Medicine&#8217;s strategic focus on advancing its </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> liver franchise, deprioritization of its CGD program, and a reduction in R&#38;D personnel resulting from the workforce reduction.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">General and Administrative (G&#38;A) Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> G&#38;A expenses were $11.2&#160;million for the three months ended September&#160;30, 2025, as compared to $14.1&#160;million for the three months ended September&#160;30, 2024. The decrease in G&#38;A expenses is primarily driven by a decrease in personnel costs resulting from the workforce reduction.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Net Loss&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Net loss was $50.6&#160;million for the three months ended September&#160;30, 2025, as compared to $52.5&#160;million for the three months ended September&#160;30, 2024.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2025, cash, cash equivalents, investments, and restricted cash were $227.0&#160;million, as compared to $204.5&#160;million as of December&#160;31, 2024.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><img alt="image.jpg" src="image.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Guidance</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating plans, Prime Medicine expects that its cash, cash equivalents and investments of $213.3&#160;million as of September&#160;30, 2025 will be sufficient to fund its operating expenses and capital expenditure requirements into </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2027.</font></div><div id="i709b8635f3dd4eed88a7c4dcc949136e_7"></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About Prime Medicine</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing&#8217;s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus&#58; liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing&#8217;s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time Prime Medicine may use its website, its X, formerly Twitter, account (&#64;PrimeMedicine) or its LinkedIn profile at https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;prime-medicine to distribute material information. Its financial and other material information is routinely posted to and accessible on the Investors section of its website, available at www.primemedicine.com. Investors are encouraged to review the Investors section of its website because the Company may post material information on that site that is not otherwise disseminated by the Company. Information that is contained in and can be accessed through the Company&#8217;s website or its social media is not incorporated into, and does not form a part of, this press release.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#169; 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.</font></div><div id="i709b8635f3dd4eed88a7c4dcc949136e_10"></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine&#8217;s beliefs and expectations regarding&#58; the significance of data from its Phase 1&#47;2 trial of PM359&#59; the planned regulatory interactions with the FDA based on the data from its Phase 1&#47;2 trial of PM359 and the outcomes of any such interactions&#59; the continued development and advancement of its CF, AATD and WD programs, including the anticipated timing of filing an IND and&#47;or CTA application for its WD program in the first half of 2027 and for its AATD program in mid-2026, and initial clinical data for both programs in 2027&#59; the potential of PM359 to address the unmet medical need for patients with CGD&#59; the initiation, timing, progress, and results of its research and development programs, preclinical studies and future clinical trials, including the release of data related thereto&#59; the potential of Prime Editing to correct the causative mutations of, and to cure, diseases, including AATD, WD, CF and CGD&#59; the potential for its universal LNP platform to precisely deliver Prime Editors and enable significant efficiencies in pre-clinical development, manufacturing and clinical development&#59; the partnership with Bristol Myers Squibb and the Cystic Fibrosis Foundation, the intended and potential benefits thereof, and its ability to enter into additional partnerships&#59; its expectations regarding the breadth of Prime Editing technology and the implementation of its strategic plans for its business, programs, and technology&#59; the potential of Prime Editing to unlock opportunities across thousands of potential indications&#59; and its expected cash runway.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><img alt="image.jpg" src="image.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with&#58; uncertainties related to Prime Medicine&#8217;s product candidates entering clinical trials&#59; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals&#59; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies&#59; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology&#59; Prime Medicine&#8217;s ability to identify and enter into future license agreements and collaborations&#59; Prime Medicine&#8217;s expectations regarding the anticipated timeline of its cash runway and future financial performance&#59; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in Prime Medicine&#8217;s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Investor and Media Contacts</font></div><div style="margin-bottom:9pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Gregory Dearborn</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prime Medicine</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">857-209-0696</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">gdearborn&#64;primemedicine.com </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Hannah Deresiewicz</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Precision AQ</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">212-362-1200</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">hannah.deresiewicz&#64;precisionaq.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div></div></div><div id="i709b8635f3dd4eed88a7c4dcc949136e_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:justify"><img alt="image.jpg" src="image.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:241px"></div></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheet Data</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investments</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">213,287&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">190,442&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">385,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">297,508&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">223,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">144,359&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">161,821&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">153,149&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Operations</font></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue &#8212; related party</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,225&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">209&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43,990&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40,340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11,208&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14,101&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55,198&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54,441&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(53,973)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(54,232)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of short-term investment &#8212; related party</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,454&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">215&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,141&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">697&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accretion (amortization) of investments</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">885&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(83)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3,391&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,714&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common stockholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50,582)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(52,518)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.32)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(0.44)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">160,503,183&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">119,764,270&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>prme-20251107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382a4ec3-91ca-422d-977a-87c88684cb64,g:f59cd3c8-7a12-4804-81c2-511ed736342b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prme="http://www.primemedicine.com/20251107" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.primemedicine.com/20251107">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prme-20251107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prme-20251107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.primemedicine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>prme-20251107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382a4ec3-91ca-422d-977a-87c88684cb64,g:f59cd3c8-7a12-4804-81c2-511ed736342b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_c36f1b76-0c0d-4782-8212-85e775c5b000_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ff4ac67e-aedc-43df-97cd-4f01c37e46d1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_797f2975-6b51-451d-a2c5-edb3e33c5854_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b11dde22-3cd0-49a7-94d7-57ba802c1b27_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_697adb31-ab0c-4029-afde-75d5b911335a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c9a36d14-0fb1-4d3b-a97c-4d9f1bd6478f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f48512bf-e3ab-4e3a-93c8-7d789da53870_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8e74c251-205e-42a4-95a9-87be9c884bde_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7537b3a8-f3b2-487a-ab0a-a7a0123eb4cb_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_715ca81d-4ffa-4ecb-8d29-684072c76662_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_c498560d-b5bb-48cb-9a45-f05789fa6e2e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5d078d9d-015b-4694-8386-18f092209f53_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_48a365ab-4f9c-41e1-a2b4-a9bc32deb9b4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6630f611-c82b-4b2e-b622-4d2f7571f7ed_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a5ee94d1-32e0-4c2a-a6e7-3a845c478037_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1b105309-d280-4691-9af5-7725c9ad414d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3533a7d6-e54f-463e-b1ac-fa28c3d5111a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fd5cb7ce-6c66-468d-9d6e-a55b4b834585_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_da472a90-13fc-4f20-9940-c66d532a6d71_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6e511058-18af-43d6-af35-df9965b65e0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_68854d6c-4c8a-4392-804e-b4f050a68bd6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_400ae256-7370-45f1-8da4-19d77945af29_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_af2ab399-0296-4884-bde8-b9be95f9c7b2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>prme-20251107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:382a4ec3-91ca-422d-977a-87c88684cb64,g:f59cd3c8-7a12-4804-81c2-511ed736342b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.primemedicine.com/role/Cover" xlink:type="simple" xlink:href="prme-20251107.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.primemedicine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8feb825b-3950-415a-9bc6-8f0117ad0728" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_DocumentType_8feb825b-3950-415a-9bc6-8f0117ad0728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_81b778cf-9d14-42c0-b398-6d0eaa0eaed4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_DocumentPeriodEndDate_81b778cf-9d14-42c0-b398-6d0eaa0eaed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5f2af0e-322f-4f0a-91ff-d3900d6c64b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityRegistrantName_a5f2af0e-322f-4f0a-91ff-d3900d6c64b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_315e4a96-7d45-4347-a317-d46c1af1e060" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityIncorporationStateCountryCode_315e4a96-7d45-4347-a317-d46c1af1e060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_46bc80bf-7322-4acf-a056-e6c8b585925c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityFileNumber_46bc80bf-7322-4acf-a056-e6c8b585925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f7910e92-948f-474d-8a0a-630788124e52" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityTaxIdentificationNumber_f7910e92-948f-474d-8a0a-630788124e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_df1f72ac-7f47-40d3-8cff-fadaa39faba1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityAddressAddressLine1_df1f72ac-7f47-40d3-8cff-fadaa39faba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fd23141b-1661-4683-9d12-db0d4f292925" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityAddressCityOrTown_fd23141b-1661-4683-9d12-db0d4f292925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_356fb140-a0dc-4874-bfd2-7093bf0fe321" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityAddressStateOrProvince_356fb140-a0dc-4874-bfd2-7093bf0fe321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b606dd5a-4188-42b5-81bb-1915d018b4a4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityAddressPostalZipCode_b606dd5a-4188-42b5-81bb-1915d018b4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d1d7d24e-49cb-4cbf-b365-9256432db45d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_CityAreaCode_d1d7d24e-49cb-4cbf-b365-9256432db45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c7647e5b-a050-49a0-928a-e77122344e2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_LocalPhoneNumber_c7647e5b-a050-49a0-928a-e77122344e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4a77f321-3faf-4016-aeb9-806fb06bd65f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_WrittenCommunications_4a77f321-3faf-4016-aeb9-806fb06bd65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2569d8dd-ada5-49af-938b-f86c7c60d179" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_SolicitingMaterial_2569d8dd-ada5-49af-938b-f86c7c60d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_1f3e9d5c-16cd-40c5-ba7d-5772755a988c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_PreCommencementTenderOffer_1f3e9d5c-16cd-40c5-ba7d-5772755a988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_16213672-8321-45b7-ab6d-e1cd8b6c5827" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_16213672-8321-45b7-ab6d-e1cd8b6c5827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0e010157-ea18-46f3-8c65-5b556e09d554" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_Security12bTitle_0e010157-ea18-46f3-8c65-5b556e09d554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0603177b-34bb-40a5-aed0-d0f5c1d1a1af" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_TradingSymbol_0603177b-34bb-40a5-aed0-d0f5c1d1a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a278e188-6de9-46d5-ad70-0a64969cfd8d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_SecurityExchangeName_a278e188-6de9-46d5-ad70-0a64969cfd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5fa72098-c3fa-4fe7-9bcc-690bb4a5183c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityEmergingGrowthCompany_5fa72098-c3fa-4fe7-9bcc-690bb4a5183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_399dfcdc-b21d-4d23-a84c-74ae5f0ea47a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityExTransitionPeriod_399dfcdc-b21d-4d23-a84c-74ae5f0ea47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_37ae4567-abf6-4198-a3c6-2fefed40fe38" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_EntityCentralIndexKey_37ae4567-abf6-4198-a3c6-2fefed40fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_77d1ec19-ba7c-4b9d-8a34-09d0a98d951f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c508e560-d6a4-4d93-af0c-f9320ceea658" xlink:to="loc_dei_AmendmentFlag_77d1ec19-ba7c-4b9d-8a34-09d0a98d951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Prime Medicine, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3097762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">60 First Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Address Line One</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">465-0013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRME<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001894562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="prme-20251107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.primemedicine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="prme-20251107.htm">prme-20251107.htm</File>
    <File>prme-20251107.xsd</File>
    <File>prme-20251107_lab.xml</File>
    <File>prme-20251107_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "prme-20251107.htm": {
   "nsprefix": "prme",
   "nsuri": "http://www.primemedicine.com/20251107",
   "dts": {
    "inline": {
     "local": [
      "prme-20251107.htm"
     ]
    },
    "schema": {
     "local": [
      "prme-20251107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prme-20251107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prme-20251107_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.primemedicine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prme-20251107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prme-20251107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.primemedicine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-25-050415-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-050415-xbrl.zip
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MFJ[6'3R:]UD#]WGQWE*O^B[O=O76LS<[ 73WW[+E)D7W'U7OW:SSNT+@1E$
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MW54B2M2/O<1@LYK])1+UYTLZ_P=02P,$%     @ 8CMG6Q[%F-5B @  " <
M !$   !P<FUE+3(P,C4Q,3 W+GAS9,U4R6[;,!"]^RM8G4OMB64C=H F"%#
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MJ;PO01XFDI2A)!H&AFM<_10/H"TN@;(@2FO*>!1L#RA\PWPO+N38N=B'MJ.
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M_/:X<U?6>4:,722P$#L7OO3@._95Q%&2*G8UDHG/_IWQ!':E^>"##'GH21[
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MEJ>]>J#R;S_R)_!CE(Z#W_X?4$L! A0#%     @ 8CMG6ZP6*AO6#@  S6<
M !$              ( !     '!R;64M,C R-3$Q,#<N:'1M4$L! A0#%
M  @ 8CMG6Q[%F-5B @  " <  !$              ( !!0\  '!R;64M,C R
M-3$Q,#<N>'-D4$L! A0#%     @ 8CMG6Z6(/&MB"@   U@  !4
M     ( !EA$  '!R;64M,C R-3$Q,#=?;&%B+GAM;%!+ 0(4 Q0    ( &([
M9UO#+&.7Y08  /\R   5              "  2L<  !P<FUE+3(P,C4Q,3 W
M7W!R92YX;6Q02P$"% ,4    " !B.V=;EDK4R,D=  #D\   'P
M    @ %#(P  <3,R,#(U."UK97@Y.3%X<')E<W-R96QE87-E+FAT;5!+!08
1    !0 % %$!  !)00     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>prme-20251107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prme-20251107.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001894562</identifier>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001894562</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Prime Medicine, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-41536</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">84-3097762</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">60 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">465-0013</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common stock, par value $.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">PRME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-21">false</dei:EntityExTransitionPeriod>
    <dei:EntityRegistrantName contextRef="c-1" id="f-22">Prime Medicine, Inc.</dei:EntityRegistrantName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
